Genomma Lab Internacional S.A.B. de C.V - Asset Resilience Ratio
Genomma Lab Internacional S.A.B. de C.V (LABB) has an Asset Resilience Ratio of 0.90% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Genomma Lab Internacional S.A.B. de C.V's Asset Resilience Ratio has changed over time. Check Genomma Lab Internacional S.A.B. de C.V strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Genomma Lab Internacional S.A.B. de C.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Genomma Lab Internacional S.A.B. de C.V.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 0% |
| Short-term Investments | MX$213.62 Million | 0.9% |
| Total Liquid Assets | MX$213.62 Million | 0.90% |
Asset Resilience Insights
- Limited Liquidity: Genomma Lab Internacional S.A.B. de C.V maintains only 0.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genomma Lab Internacional S.A.B. de C.V Industry Peers by Asset Resilience Ratio
Compare Genomma Lab Internacional S.A.B. de C.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Alkermes plc
F:8AK |
Drug Manufacturers - Specialty & Generic | 3.76% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
Annual Asset Resilience Ratio for Genomma Lab Internacional S.A.B. de C.V (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Genomma Lab Internacional S.A.B. de C.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.90% | MX$213.62 Million ≈ $12.29 Million |
MX$23.83 Billion ≈ $1.37 Billion |
+0.53pp |
| 2024-12-31 | 0.37% | MX$89.25 Million ≈ $5.14 Million |
MX$24.08 Billion ≈ $1.39 Billion |
-0.51pp |
| 2023-12-31 | 0.89% | MX$183.23 Million ≈ $10.55 Million |
MX$20.70 Billion ≈ $1.19 Billion |
-0.07pp |
| 2022-12-31 | 0.95% | MX$205.93 Million ≈ $11.85 Million |
MX$21.61 Billion ≈ $1.24 Billion |
+0.81pp |
| 2017-12-31 | 0.15% | MX$23.21 Million ≈ $1.34 Million |
MX$15.89 Billion ≈ $914.23 Million |
-0.15pp |
| 2015-12-31 | 0.30% | MX$52.07 Million ≈ $3.00 Million |
MX$17.63 Billion ≈ $1.01 Billion |
+0.23pp |
| 2014-12-31 | 0.07% | MX$17.84 Million ≈ $1.03 Million |
MX$25.43 Billion ≈ $1.46 Billion |
+0.02pp |
| 2013-12-31 | 0.05% | MX$8.13 Million ≈ $467.65K |
MX$17.35 Billion ≈ $998.66 Million |
-0.21pp |
| 2012-12-31 | 0.25% | MX$32.75 Million ≈ $1.88 Million |
MX$12.99 Billion ≈ $747.73 Million |
-6.55pp |
| 2007-12-31 | 6.81% | MX$81.26 Million ≈ $4.68 Million |
MX$1.19 Billion ≈ $68.72 Million |
-- |
About Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products t… Read more